EnglishFrenchGermanItalianSpanish

WELCOME TO THE NEWSROOM

WATCH OUR LATEST VIDEO

In the news

Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.

The NeuMoDx™ 288 Molecular System is designed for the automated extraction and isolation of nucleic acids, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. The NeuMoDx™ 288 Molecular System consists of the instrument with touchscreen computer, accessories and reagents and consumables. Learn more about the NeuMoDx™ 288...

NeuMoDx™ plans to deliver 11 CE-IVD assays to QIAGEN by the end of 2019 on NeuMoDx™ System as part of aggressive menu expansion plans, including blood-borne viruses, women’s health and transplantation assays   Hilden, Germany, and Ann Arbor, Michigan, April 11, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx™ Molecular, Inc....

Ann Arbor, MI and Salt Lake City, UT (April, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, and XCR Diagnostics, a sample-to-result systems company focused on actionable near patient results in 10 minutes or less, have announced today a chemistry license partnership to develop and implement three XCR® assays...

NeuMoDx™ Announces Completion of Series B Financing Funds Product Development for High Throughput Molecular Diagnostic Platform Ann Arbor, Michigan (March 26, 2014) – NeuMoDx™ Molecular, Inc., a privately held diagnostics company developing a new platform for high throughput, low cost molecular testing, today announced completion of its Series B financing. Pfizer Ventures led the $21 million...